Glaukos Corporation

Glaukos Corporation

GKOSNYSE / NASDAQHealthcareMid cap

$237.31-$0.79 (-0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$7.1B
P/E
-38.1x
EV / EBITDA
-49.0x
Revenue
$507.4M
Net margin
-37.0%
ROCE
-25.2%

+149.3% over the last year

Glaukos Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+36.8%
3M
+28.4%
6M
+65.0%
1Y
+149.3%
5Y
+393.3%

52-week range

Day change -$0.79 (-0.3%) from $238 to $237 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GKOS, bought on each weekday since 2021.

News & filings

What Glaukos filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 188 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 57.9% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.

Read moreShow less

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Sector
Healthcare
Shares outstanding
57.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.1B
P/E
-38.1x
P/B
10.9x
EV / EBITDA
-49.0x
EV / Sales
14.1x
P/S
14.1x
52-week high
$247.16
52-week low
$95.20

Profitability

Operating margin
-39.3%
Net margin
-37.0%
EBITDA margin
-28.8%
ROE
-28.6%
ROCE
-25.2%
ROA
-21.0%
Asset turnover
0.57

Growth

Revenue
$507.4M
Revenue growth, 1Y
32.3%
Revenue CAGR, 3Y
21.5%
Net profit growth, 1Y
28.2%
Free cash flow
-$39.1M

Solvency

Current ratio
4.69
Debt / Equity
0.16
Debt / Assets
0.12
CFO / Net profit
0.08
Cash / Market cap
1.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$507.4M
Cost of revenue$224.7M
Gross profit$282.8M
Operating expenses$482.4M
Research and development$150.6M
Selling, general and administrative$331.8M
Operating income-$199.6M
Interest and other$6.6M
Pretax income-$193.0M
Tax and other-$5.3M
Net income-$187.7M

Revenue and net profit

Revenue grew 32.3% in FY2025; net profit is the dashed line.

Glaukos Corporation revenue and net profit by fiscal year
Glaukos Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$282.9M-$99.2M
FY2023$314.7M-$134.7M
FY2024$383.5M-$146.4M
FY2025$507.4M-$187.7M

Cash flows

FY2025: -$14.8M from operations, -$39.1M free after investment (dashed).

Glaukos Corporation operating and free cash flow by fiscal year
Glaukos Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$33.1M-$63.3M
FY2023-$57.8M-$78.0M
FY2024-$61.3M-$67.6M
FY2025-$14.8M-$39.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$507.4M+32.3%1Y
EBITDA
-$146.1M
Net profit
-$187.7M
Cash from operations
-$14.8M
Free cash flow
-$39.1M
Revenue CAGR, 3Y
21.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$507.4M-$146.1M-$187.7M-$39.1M-28.6%+32.3%+28.2%

Monthly returns

Month-by-month returns of GKOS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$893.5M
Liabilities$237.3M
Equity$656.2M
Paid-in capital$1.6B
Retained earnings-$933.1M
Treasury stock$130.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GKOS highlighted.

P/E against peers

GKOS has no positive P/E; the peer median is 17.9x.

Not shown (no positive earnings and no EV / Sales): Glaukos Corporation, Protagonist Therapeutics, Inc., Teleflex Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Glaukos CorporationGKOSthis company$7.1B-38.1x10.9x-28.6%-49.0x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
TG Therapeutics, Inc.TGTX$6.2B13.9x9.6x69.0%47.5x
PTC Therapeutics, Inc.PTCT$5.9B8.6x—-332.5%7.5x
Teleflex IncorporatedTFX$5.8B-6.5x1.9x-29.0%27.1x
Peer median—17.9x4.3x8.0%24.0x

Year-to-date ROI

GKOS since 1 January, against earlier years.

Historical volatility

GKOS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Glaukos Corporation operating margin by fiscal year
Glaukos Corporation operating margin by fiscal year
DateOperating margin
FY2022-36.2%
FY2023-39.3%
FY2024-28.2%
FY2025-39.3%
LineFY2025
Cost of revenueCost Of Revenue$224.7M
Gross profitGross Profit$282.8M
Operating expensesOperating Expense$482.4M
Research and developmentResearch And Development$150.6M
Selling, general and administrativeSelling General And Administration$331.8M
Total expensesTotal Expenses$707.0M
Pretax incomePretax Income-$193.0M

Learn while you research

Academy chapters picked for Glaukos Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing32% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →